All publications

All publications :  出版物一覧

1. Laird, M., Matsumoto, K., Higashi, Y., Komatsu, A., Raitano, A., Morrison, K., Suzuki, M., and Tamanoi, F. (2023) Organosilica nanoparticles containing sodium borocaptate (BSH) provide new perspectives for boron neutron capture therapy (BNCT): efficient cellular uptake and enhanced BNCT efficacy. Nanoscale Advances, doi: 10.1039/D2NA00839D.  

2. Tamanoi, F. (2023)「オージェ電子と放射線治療」, 放射線生物研究, 58, 1, 69-79.

3. Higashi, Y., Ikeda, S., Matsumoto, K., Satoh, S., Komatsu, A., Sugiyama, H. and Tamanoi, F. (2022) Tumor Accumulation of PIP-Based KRAS Inhibitor KR12 Evaluated by the Use of a Simple, Versatile Chicken Egg Tumor Model. Cancers. 14, 951. doi: 10.3390/cancers14040951

4. Komatsu, A., Matsumoto, K., Yoshimatsu, Y., Sin, Y., Kubota, A., Saito, T., Mizumoto, A., Ohashi, S., Muto, M., Noguchi, R., Kondo, T. and Tamanoi, F. (2021) The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine. Cells. 10, 2613. doi: 10.3390/cells10102613. 

5. Higashi, Y., Matsumoto, K., Saitoh, H., Shiro, A., Ma, Y., Laird, M., Chinnathambi, S., Birault, A., Doan, T.L.H., Yasuda, R., Tajima, T., Kawachi, T. and Tamanoi, F. (2021) Iodine containing porous organosilica nanoparticles trigger tumor spheroids destruction upon monochromatic X-ray irradiation: DNA breaks and K-edge energy X-ray. Sci. Rep. 11, 14192. doi: 10.1038/s41598-021-93429-9.

6. Gisbert-Garzarán, M., Lozano, D., Matsumoto, K., Komatsu, A., Manzano, M., Tamanoi, F. and Vallet-Regí, M. (2021) Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape. ACS Appl Mater Interfaces. 13, 9656-9666. doi: 10.1021/acsami.0c21507.

7. Tamanoi, F., Chinnathambi, S., Laird, M., Komatsu, A., Birault, A., Takata, T., Doan, T.L., Mai, N.X.D., Raitano, A., Morrison, K., Suzuki, M. and Matsumoto, K. (2021) Construction of Boronophenylalanine-Loaded Biodegradable Periodic Mesoporous Organosilica Nanoparticles for BNCT Cancer Therapy. Int. J. Mol. Sci. 22, 2251. doi: 10.3390/ijms22052251.

8. Chinnathambi, S. and Tamanoi, F. (2020) Recent Development to Explore the Use of Biodegradable Periodic Mesoporous Organosilica (BPMO) Nanomaterials for Cancer Therapy. Pharmaceutics. 12, 890. doi: 10.3390/pharmaceutics12090890.

9. Tamanoi, F., Matsumoto, K., Saitoh, H. and Shiro, A. (2020)「単色X 線とナノ粒子を組み合わせた新しいがん治療技術の開発にむけて」, Isotope News〔No.770〕2020年8月号, pp.7-11.

10. Tamanoi, F., Matsumoto, K., Doan, T.L.H., Shiro, A. and Saitoh, H. (2020)  Studies on the Exposure of Gadolinium Containing Nanoparticles with Monochromatic X-rays Drive Advances in Radiation Therapy. Nanomaterials (Basel). 10, 1341. doi: 10.3390/nano10071341.

11. Mai, N.X.D., Birault, A., Matsumoto, K., Ta, H.K.T., Intasa-Ard, S.G., Morrison, K., Thang, P.B., Doan, T.L.H. and Tamanoi, F. (2020) Biodegradable Periodic Mesoporous Organosilica (BPMO) Loaded with Daunorubicin: A Promising Nanoparticle-Based Anticancer Drug. ChemMedChem. 15, 593-599. doi: 10.1002/cmdc.201900595.

12. Komatsu, A., Matsumoto, K. and Tamanoi, F.(2019) 「がんの鶏卵モデル」, 実験医学別冊：患者由来がんモデル実験ガイド, 第5章, 2019年10月1日.

13. Matsumoto, K., Saitoh, H., Doan, T.L.H., Shiro, A., Nakai, K., Komatsu, A., Tsujimoto, M., Yasuda, R., Kawachi, T., Tajima, T. and Tamanoi, F. (2019) Destruction of tumor mass by gadolinium-loaded nanoparticles irradiated with monochromatic X-rays: Implications for the Auger therapy. Sci .Rep. 9, 13275. doi: 10.1038/s41598-019-49978-1. 

14. Mekaru, H., Yoshigoe, A., Nakamura, M., Doura, T., Tamanoi, F. (2019)  Biodegradability of Disulfide-Organosilica Nanoparticles Evaluated by Soft X-ray Photoelectron Spectroscopy: Cancer Therapy Implications. ACS Applied Nano Materials, 2, 479-488. doi: 10.1021/acsanm.8b02023.

15. Komatsu, A., Matsumoto, K., Saito, T., Muto, M. and Tamanoi F. (2019)  Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues. Cells. 8, 440. doi: 10.3390/cells8050440. 

16. Tamanoi, F., Endo, Y., Uto, Y., Kusuhashi, Y., Futawaka, M., Matsumoto, K. (2018) Chicken egg tumor model and its application in personalized medicine, Jikken Igaku. Vol. 37, No. 1, 2019.

17. Vu, B.T., Shahin, S.A., Croissant, J., Fatieiev, Y., Matsumoto, K., Le-Hoang Doan, T., Yik, T., Simargi, S., Conteras, A., Ratliff, L., Jimenez, C.M., Raehm, L., Khashab, N., Durand, J.O., Glackin, C. and Tamanoi, F. (2018) Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Sci. Rep. 8, 8524. doi: 10.1038/s41598-018-25573-8.  

18. Shahin, S.A., Wang, R., Simargi, S.I., Contreras, A., Parra Echavarria, L., Qu, L., Wen, W., Dellinger, T., Unternaehrer, J., Tamanoi, F., Zink, J.I. and Glackin, C.A. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine. 14, 1381-1394. doi: 10.1016/j.nano.2018.04.008. 

19. Faridi, N., Bathaie, S.Z., Abroun, S., Farzaneh, P., Karbasian, H., Tamanoi,  F. and Mohagheghi, M.A. (2018) Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women's breast cancer tumors. Cytotechnology.  70, 625-639. doi: 10.1007/s10616-017-0159-3.  

20. Heard, J.J., Phung, I., Potes, M.I. and Tamanoi, F. (2018) An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. BMC Cancer. 18, 69. doi: 10.1186/s12885-017-3938-5. 

21. Tanaka, A., Radwan, M.O., Hamasaki, A., Ejima, A., Obata, E., Koga, R., Tateishi, H., Okamoto, Y., Fujita, M., Nakao, M., Umezawa, K., Tamanoi, F. and Otsuka, M. (2017) A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. Bioorg. Med. Chem. Lett.  27, 3862-3866. doi: 10.1016/j.bmcl.2017.06.047. 

22. Roberts, C.M., Shahin, S.A., Wen, W., Finlay, J.B., Dong, J., Wang, R., Dellinger, T.H., Zink, J.I., Tamanoi, F. and Glackin, C.A. (2017)  Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. Nanomedicine. 13, 965-976. doi: 10.1016/j.nano.2016.11.010. 

23. Hayashi, J.Y. and Tamanoi, F. (2017) Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy. Enzymes.  42, 153-172. doi: 10.1016/bs.enz.2017.08.005. 

24. Bathaie, S.Z., Ashrafi, M., Azizian, M. and Tamanoi, F. (2017) Mevalonate Pathway and Human Cancers. Curr. Mol. Pharmacol. 10, 77-85. doi: 10.2174/1874467209666160112123205. 

25. Croissant, J.G., Fatieiev, Y., Julfakyan, K., Lu, J., Emwas, A.H., Anjum, D.H., Omar, H., Tamanoi, F., Zink, J.I. and Khashab, N.M. (2016) Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. Chemistry. 22, 14806-14811. doi: 10.1002/chem.201601714. 

26. Croissant, J.G., Fatieiev, Y., Omar, H., Anjum, D.H., Gurinov, A., Lu, J., Tamanoi, F., Zink, J.I. and Khashab, N.M. (2016) Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells. Chemistry. 22, 9607-15. doi: 10.1002/chem.201600587.

27. Croissant, J.G., Zhang, D., Alsaiari, S., Lu, J., Deng, L., Tamanoi, F., AlMalik,  A.M., Zink, J.I. and Khashab, N.M. (2016) Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. J Control Release. 229, 183-191. doi: 10.1016/j.jconrel.2016.03.030. 

28. Mekaru, H., Lu, J. and Tamanoi, F. (2015) Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. Adv. Drug. Deliv. Rev. 95, 40-9. doi: 10.1016/j.addr.2015.09.009. 

29. Finlay, J., Roberts, C.M., Dong, J., Zink, J.I., Tamanoi, F. and Glackin, C.A. (2015) Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomedicine. 11, 1657-66. doi: 10.1016/j.nano.2015.05.011. 

30. Lu, J., Yoshimura, K., Goto, K., Lee, C., Hamura, K., Kwon, O. and Tamanoi,  F. (2015) Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. PLoS One. 10, e0137595. doi: 10.1371/journal.pone.0137595.  

31. Chantaravisoot, N., Wongkongkathep, P., Loo, J.A., Mischel, P.S. and  Tamanoi, F. (2015) Significance of filamin A in mTORC2 function in glioblastoma. Mol. Cancer.14, 127. doi: 10.1186/s12943-015-0396-z. 

32. Mortazavi, F., Lu, J., Phan, R., Lewis, M., Trinidad, K., Aljilani, A., Pezeshkpour, G. and Tamanoi, F. (2015) Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. BMC Cancer. 15, 381. doi: 10.1186/s12885-015-1360-4. 

33. Hwang, A.A., Lu, J., Tamanoi, F. and Zink, J.I. (2015) Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. Small. 11, 319-328. doi: 10.1002/smll.201400765.

34. Sato, T., Akasu, H., Shimono, W., Matsu, C., Fujiwara, Y., Shibagaki, Y., Heard, J.J., Tamanoi, F. and Hattori, S. (2015) Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity. J. Biol. Chem. 290, 1096-105. doi: 10.1074/jbc.M114.592402.

35. Heard, J.J., Fong, V., Bathaie, S.Z. and Tamanoi, F. (2014) Recent progress in the study of the Rheb family GTPases. Cell Signal. 26, 1950-7. doi: 10.1016/j.cellsig.2014.05.011. 

36. Théron, C., Gallud, A., Carcel, C., Gary-Bobo, M., Maynadier, M., Garcia, M., Lu, J., Tamanoi, F., Zink, J.I. and Wong Chi Man, M. (2014) Hybrid mesoporous silica nanoparticles with pH-operated and complementary H-bonding caps as an autonomous drug-delivery system. Chemistry. 20, 9372-80. doi: 10.1002/chem.201402864. 

37. Nakashima, A., Kamada, S., Tamanoi, F. and Kikkawa, U. (2014) Fission yeast arrestin-related trafficking adaptor, Arn1/Any1, is ubiquitinated by Pub1 E3 ligase and regulates endocytosis of Cat1 amino acid transporter. Biol. Open. 3, 542-52. doi: 10.1242/bio.20148367. 

38. Croissant, J., Chaix, A., Mongin, O., Wang, M., Clément, S., Raehm, L., Durand, J.O., Hugues, V., Blanchard-Desce, M., Maynadier, M., Gallud, A., Gary-Bobo, M., Garcia, M., Lu, J., Tamanoi, F., Ferris, D.P., Tarn, D. and Zink, J.I. (2014) Two-photon-triggered drug delivery via fluorescent nanovalves. Small. 10, 1752-5. doi: 10.1002/smll.201400042.  

39. Coffman, K., Yang, B., Lu, J., Tetlow, A.L., Pelliccio, E., Lu, S., Guo, D.C., Tang,  C., Dong, M.Q. and Tamanoi, F. (2014) Characterization of the Raptor/4E-BP1 interaction by chemical cross-linking coupled with mass spectrometry analysis. J. Biol. Chem. 289, 4723-4734. doi: 10.1074/jbc.M113.482067. 

40. Croissant, J., Maynadier, M., Gallud, A., Peindy N'dongo, H., Nyalosaso, J.L., Derrien, G., Charnay, C., Durand, J.O., Raehm, L., Serein-Spirau, F., Cheminet, N., Jarrosson, T., Mongin, O., Blanchard-Desce, M., Gary-Bobo, M., Garcia, M., Lu, J., Tamanoi, F., Tarn, D., Guardado-Alvarez, T.M. and  Zink, J.I. (2013) Two-photon-triggered drug delivery in cancer cells using nanoimpellers. Angew. Chem. Int. Ed. Engl. 52, 13813-7. doi: 10.1002/anie.201308647.  

41. Akhavan, D., Pourzia, A.L., Nourian, A.A., Williams, K.J., Nathanson, D., Babic, I., Villa, G.R., Tanaka, K., Nael, A., Yang, H., Dang, J., Vinters, H.V., Yong, W.H., Flagg, M., Tamanoi, F., Sasayama, T., James, C.D., Kornblum,  H.I., Cloughesy, T.F., Cavenee, W.K., Bensinger, S.J. and Mischel, P.S. (2013) De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discovery, 3, 534-547. doi: 10.1158/2159-8290. 

42. Zimonjic, D.B., Chan, L.N., Tripathi, V., Lu, J., Kwon, O., Popescu, N.C., Lowy,  D.R., Tamanoi, F. (2013) In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. BMC Cancer. 13, 198. doi: 10.1186/1471-2407-13-198. 

43. Yanes, R.E., Tarn, D., Hwang, A.A., Ferris, D.P., Sherman, S.P., Thomas, C.R., Lu, J., Pyle, A.D., Zink, J.I. and Tamanoi, F. (2013) Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. Small. 9, 697. doi: 10.1002/smll.201201811.  

44. Rettig, M., Trinidad, K., Pezeshkpour, G., Frost, P., Sharma, S., Moatamed, F., Tamanoi, F. and Mortazavi, F. (2012) PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. PLoS One. 7, e42012. doi: 10.1371/journal.pone.0042012. 

45. Nakashima, A., Otsubo, Y., Yamashita, A., Sato, T, Yamamoto, M. and Tamanoi, F. (2012) Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 as S6 kinase. J. Cell. Sci. 125, 5840-5849. doi: 10.1242/jcs.111146. 

46. Lau, Y.A., Henderson, B.L., Lu, J., Ferris, D.P., Tamanoi, F. and Zink, J.I. (2012) Continuous spectroscopic measurements of photo-stimulated release of molecules by nanomachines in a living cell. Nanoscale 4, 3482-3489. doi: 10.1039/c2nr30524k.  

47. Yanes, R.E. and Tamanoi, F. (2012) Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Therapeutic Delivery 3, 389-404. doi: 10.4155/tde.12.9. 

48. Lu, J., Li, Z., Zink, J.I. and Tamanoi, F. (2012) In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine. 8, 212-220. doi: 10.1016/j.nano.2011.06.002. 

49. Chan, L.N., Fiji, H.D., Watanabe, M., Kwon, O. and Tamanoi, F. (2011) Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I. PLoS One 6, e2613. doi: 10.1371/journal.pone.0026135. 

50. Ferris, D.P., Lu, J., Gothard, C., Yanes, R., Thomas, C.R., Olsen, J.C., Stoddart,  J.F., Tamanoi, F. and Zink, J.I. (2011) Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small. 7, 1816-1826. doi: 10.1002/smll.201002300. 

51. Xue, M., Zhong, X., Shaposhnik, Z., Qu, Y., Tamanoi, F., Duan, X. and Zink,  J.I. (2011) pH-Operated mechanized porous silicon nanoparticles. J. Am. Chem. Soc.  133, 8798-801. doi: 10.1021/ja201252e. 

52. Tamanoi, F. (2011) Ras signaling in yeast. Genes Cancer 2, 210-215 doi: 10.1177/1947601911407322. 

53. Hardt, M., Chantaravisoot, N. and Tamanoi, F. (2011) Activating mutations of TOR (target of rapamycin). Genes Cells. 16, 141-51. doi: 10.1111/j.1365-2443.2010.01482.x. 

54. Meng, H., Xue, M., Xia, T., Zhao, Y.L., Tamanoi, F., Stoddart, J.F., Zink, J.I.  and Nel, A.E. (2010) Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. J. Am. Chem. Soc. 132, 12690-7. doi: 10.1021/ja104501a.  

55. Lu, J., Liong, M., Li, Z., Zink, J. and Tamanoi, F. (2010) Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 6, 1794-805. doi: 10.1002/smll.201000538. 

56. Jiang, H., Song, C., Chen, C.C., Xu, R., Raines, K.S., Fahimian, B.P., Lu, C.H., Lee, T.K., Nakashima, A., Urano, J., Ishikawa, T., Tamanoi, F. and Miao, J. (2010) Quantitative 3D imaging of whole, unstained cells by using X-ray diffraction microscopy. PNAS. 107, 11234-9. doi: 10.1073/pnas.1000156107.

57. Hom, C., Lu, J., Liong, M., Luo, H., Li, Z., Zink, J.I. and Tamanoi, F. (2010) Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small. 6, 1185-90. doi: 10.1002/smll.200901966. 

58. Sato, T., Nakashima, A., Guo, L., Coffman, K. and Tamanoi, F. (2010) Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene. 29, 2746-52. doi: 10.1038/onc.2010.28. 

59. Nakashima, A., Sato, T. and Tamanoi F. (2010) Fission yeast TORC1 regulate phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin. J. Cel.l Sci. 123(Pt 5), 777-86. doi: 10.1242/jcs.060319. 

60. Hanker, A.B., Mitin, N., Wilder, R.S., Henske, E.P., Tamanoi, F., Cox, A.D. and Der, C.J. (2010) Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. Oncogene. 29, 380-91 doi: 10.1038/onc.2009.336. 

61. Sato, T., Nakashima, A. and Tamanoi, F. (2010) Rheb-mTOR signaling pathway involved in tumor formation. Tanpakushitsu Kakusan Koso. 55, 11-7. Japanese.

62. Chantaravisoot, N. and Tamanoi F. (2010) TOR Signaling and Human Cancer. The Enzymes. 28: 301-314.

63. Parmar, N. and Tamanoi F. (2010) Rheb G-Proteins and the activation of mTORC1. The Enzymes. 27: 39-53.

64. Chan, L.N., Hart,C., Guo, L., Nyberg, T., Davides, B.S.J, Fong, L.G., Young, S.G., Agnew, B.J., Tamanoi, F. (2009) A novel approach to tag and identify geranylgeranylated proteins. Electrophoresis. 30, 3598-3606. doi: 10.1002/elps.200900259. 

65. Lu, J., Chan, L., Fiji, H.D.G., Dahl, R., Kwon, O. and Tamanoi, F. (2009) In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I, Mol. Cancer Ther. 8, 1218-1226. doi: 10.1158/1535-7163.MCT-08-1122. 

66. Kugawa, F., Suzuki, T., Miyata, M., Tomono, K. and Tamanoi, F. (2009) Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie 64, 296-300.

67. Sato, T., Nakashima, A., Guo, L. and Tamanoi, F. (2009) Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J. Biol. Chem. 284, 12783-12791. doi: 10.1074/jbc.M809207200. 

68. Zhou, J., Vos, C.C., Gjyrezi, A., Yoshida, M., Khuri, F.R., Tamanoi, F. and Giannakakou, P. (2009) The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. J. Biol. Chem. 284, 9648-9655. doi: 10.1074/jbc.M808708200. 

69. Klichko, Y., Liong, M., Choi, E., Angelos, S., Nel, A.E., Stoddart, J.F., Tamanoi, F. and Zink, J.I. (2009) Mesoporous silica for optical functionality, nanomachines, and drug delivery. J. Am. Ceram. Soc. 92, S2-S10. doi: 10.1111/j.1551-2916.2008.02722.x. 

70. Davies, B.S., Yang, S.H., Farber, E., Lee, R., Buck, S.B., Andres, D.A., Spielmann, H., Agnew, B.J., Tamanoi, F., Fong, L.G. and Young, S.G. (2009) Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome. J. Lipid Res. 50, 126-134. doi: 10.1194/jlr.M800424-JLR200. 

71. Short, J.D., Houston, K.D., Dere, R., Cai, S.L., kim, J., Johnson, C.L., Broaddus, R.R., Shen, J., Miyamoto, S., Tamanoi, F., Kwiatkowski, D., Mills, G.B. and Walker, C.L. (2008) AMP-activated protein kinase signalin results in cytoplasmic sequestration of p27. Cancer Res. 68, 6496-6506. doi: 10.1158/0008-5472.  

72. Liong, M., Lu, J., Kovochich, M., Xia, T., Ruehm, S.G., Nel, A.E., Tamanoi, F. and Zink, J.I. (2008) Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS NANO 2, 889-896. doi: 10.1021/nn800072t. 

73. Aspuria, P.J. and Tamanoi, F. (2008) The TSC/Rheb/TOR signaling pathway controls basic amino acid uptake via the Cat1 permease in fission yeast. Mol. Genet. Genomics. 279, 441-450. doi: 10.1007/s00438-008-0320-y. 

74. Sato, T., Umetsu, A. and Tamanoi, F. (2008) Characterization of the Rheb-mTOR signaling pathway in mammalian cells: Constitutive active mutants of Rheb and mTOR. Methods Enzymol. 438, 307-320. doi: 10.1016/S0076-6879(07)38021-X. 

75. Lu, J., Choi, E., Tamanoi, F. and Zink, J.I. (2008) Light-activated nanoimpellers controlled drug release in cancer cells. Small 4, 421-426. doi: 10.1002/smll.200700903. 

76. Watanabe, M., Fiji, H.D., Guo, L., Chan, L., Kinderman, S.S., Slamon, D.J., Kwon, O. and Tamanoi, F. (2008) Inhibitors of protein geranylgeranyltransferase-I and Rab geranylgeranyltransferase identified from a library of allenoate derived compounds. J. Biol. Chem. 283, 9571-9579. doi: 10.1074/jbc.M706229200. 

77. Ikeda, K., Morigasaki, S., Tatebe, H., Tamanoi, F. and Shiozaki, K., (2008) Fission yeast TOR complex 2 activates the AGC-family Gad8 kinase essential for stress resistance and cell cycle control. Cell Cycle 7, 358-364. doi: 10.4161/cc.7.3.5245. 

78. Lu, J., Liong, M., Sherman, S., Xia, T., Kovochich, M., Nel. A.E., Zink, J.I. and Tamanoi, F. (2007) Mesoporous silica nanoparticles for cancer therapy: Energy-dependent cellular uptake and delivery of paclitaxel to cancer cells. NanoBiotechnology 3, 89-95. doi: 10.1007/s12030-008-9003-3. 

79. Lu, J., Liong, M., Zink, J.I. and Tamanoi, F. (2007) Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3, 1341-1346. doi: 10.1002/smll.200700005. 

80. Aspuria, P.J., Sato, T. and Tamanoi, F. (2007) The TSC/Rheb/TOR signaling pathway in fission yeast and mammalian cells: Temperature sensitive and constitutive active mutants of TOR. Cell Cycle, 6, 1692-1695. doi: 10.4161/cc.6.14.4478. 

81. Castellano, S., Fiji, H.D., Kinderman, S.S., Watanabe, M., Leon, P.D., Tamanoi, F. and Kwon, O. (2007) Small molecule inhibitors of protein geranylgeranyltransferase type I. J. Am. Chem. Soc. 129, 5843-5845. doi: 10.1021/ja070274n. 

82. Yu, F., Harada, J.N., Brown, H.J., Deng, H., Song, M.J., Wu, T-T., Kato-Stankiewicz, J., Nelson, C.G., Vieira, J., Tamanoi, F., Chanda, S.K. and Sun, R. (2007) Systematic identification of cellular signals reactivating Kaposi’s sarcoma-associated herpesvirus. PLOS Pathogen, 3, e44. doi: 10.1371/journal.ppat.0030044. 

83. Matsuo, T., Ohtsubo, Y., Urano, J., Tamanoi, F. and Yamamoto, M. (2007) Loss of the TOR kinase Tor2 mimics nitrogen starvation and activates the sexual development pathway in fission yeast. Mol. Cell. Biol. 27, 3154-3164. doi: 10.1128/MCB.01039-06. 

84. Urano, J., Sato, T., Matsuo, T., Ohtsubo, Y., Yamamoto, M. and Tamanoi, F. (2007) Point mutations in TOR confer Rheb-indepedent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells.  Proc. Natl. Acad. Sci. USA 104, 3514-3519. doi: 10.1073/pnas.0608510104. 

85. Thapar, N. and Tamanoi, F. (2007) Studies of Protein Farnesylation in Yeast. In Yeast as a Tool in Cancer Research. eds. Nitiss, J.L. and Heitman, J., Springer, pp. 101-122. doi: 10.1007/978-1-4020-5963-6_4. 

86. Gelb, M.H., Brunsveld, L., Hrycyna, C.A., Michaelis, S., Tamanoi, F., Van Voorhis, W.C. and Waldmann, H. (2006) Therapeutic intervention based on protein prenylation and associated modifications. Nature Chem. Biol. 10, 518-528. doi: 10.1038/nchembio818. 

87. Patel, P.H. and Tamanoi, F. (2006) Increased Rheb/TOR signaling enhances sensitivity of the whole organism to oxidative stress. J. Cell. Sci. 119, 4285-4292. doi: 10.1242/jcs.03199. 

88. Ikeda, A., Shankar, D.B., Watanabe, M., Tamanoi, F., Moore, T.B. and Sakamoto, K.M. (2006) Molecular targets and the treatment of myeloid leukemia. Mol. Genet. Metab. 88, 216-224. doi: 10.1016/j.ymgme.2006.03.011. 

89. Tabancay, A.P.Jr., Comiso, M.J. and Tamanoi, F. (2006) RAS family G-proteins in Saccharomyces cerevisiae and Schizosaccharomyces pombe. In RAS family GTPases, ed. Der, C., Springer, pp. 227-256. doi: 10.1007/1-4020-4708-8_10. 

90. Patel, P.H. and Tamanoi, F. (2006) Using Drosophila and yeast genetics to investigate a role for the Rheb GTPase in cell growth. Methods in Enzymol. 407. 443-454. doi: 10.1016/S0076-6879(05)07036-9. 

91. Khazak, V. Kato-Stankiewicz, J., Tamanoi, F, and Golemis, E.A. (2006) Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interaction. Methods in Enzymol. 407. 612-629. doi: 10.1016/S0076-6879(05)07048-5. 

92. Urano, J., Comiso, M.J., Guo, L., Aspuria, P-J., Deniskin, R., Tabancay, A.P. Jr., Kato Stankiewicz, J. and Tamanoi, F. (2005) Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast. Mol. Microbiol. 58, 1074-1086. doi: 10.1111/j.1365-2958.2005.04877.x. 

93. Gau, C.L., Kato-Stankiewicz, J., Jiang, C., Miyamoto, S., Guo, L. and Tamanoi, F. (2005) Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and insensitive pathways. Molec. Cancer Therap. 4, 918-926. doi: 10.1158/1535-7163.MCT-04-0347. 

94. Aspuria, P-J. and Tamanoi, F. (2004) The Rheb family of GTP-binding proteins. Cellular Signaling 16, 1105-1112. doi: 10.1016/j.cellsig.2004.03.019. 

95. Kho, Y., Kim, S.C., Jiang, C., Barma, D., Kwon, S.W., Cheng, J., Weinbaum, C., Tamanoi, F., Falck, J. and Zhao, Y. (2004) A tagging-via-substrate technology for detection and proteomics of farnesylated proteins.  Proc. Natl. Acad. Sci. USA 101, 12479-12484. doi: 10.1073/pnas.0403413101. 

96. Uhlmann, E.J., Li, W., Scheidenhelm, D.K., Gau, C.L., Tamanoi, F. and Gutmann, D.H. (2004) Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia, 47, 180-188. doi: 10.1002/glia.20036. 

97. Clarke, S. and Tamanoi, F. (2004) Fighting cancer by disrupting C-terminal methylation of signaling proteins. J. Clin. Invest. 113, 513-515. doi: 10.1172/JCI21059. 

98. Tabancay, A.P.Jr., Gau, C-L., Machado, I.M.P., Uhlmann, E.J., Gutmann, D.H., Guo, L. and Tamanoi, F. (2003) Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J. Biol. Chem. 278, 39921-39930. doi: 10.1074/jbc.M306553200. 

99. Patel, P.H., Thapar, N., Guo, L., Martinez, M., Maris, J., Gau, C-L., Lengyel, J.A. and Tamanoi, F. (2003) Drosphila Rheb GTPase is required for cell cycle progression and cell growth.  J. Cell Sci. 116, 3601-3610. doi: 10.1242/jcs.00661.  

100. Hamasaki, A., Naka, H., Tamanoi, F., Umezawa, K. and Otsuka, M. (2003) A novel metal-chelating inhibitor of protein farnesyltransferase. Bioorg. Med. Chem. Lett. 13, 1523-1526. doi: 10.1016/s0960-894x(03)00183-5. 

101. Kato-Stankiewicz, J., Hakim, I., Zhi, G., Zhang, J., Serebriiskii, I., Guo, L., Edamatsu, H., Koide, H., Menon, S., Eckl, R., Sakamuri, S., Lu, V., Chen, Q., Agarwal, S., Baumbach, W.R., Golemis, E.A., Tamanoi, F. and Khazak, V. (2002) Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc. Natl. Acad. Sci. USA 99, 14398-14403. doi: 10.1073/pnas.222222699. 

102. Tamanoi, F., Kato-Stankiewicz, J., Jiang, C., Machado, I. and Thapar, N. (2001) Farnesylated proteins and cell cycle progression.  J. Cell. Biochem. 37, 6-70. doi: 10.1002/jcb.10067.

103. Jiang, C., Kato-Stankiewicz, J., Gau, C.L. and Tamanoi, F. (2001) Effects of farnesyltransferase inhibitors on cell cycle progression of human cancer cells. Gene Funct. Dis. 2, 2/3, 1-9.

104. Finlin, B.S., Gau, C.L., Murphy, G.A., Shao, H., Kimel, T., Seitz, R.S., Chiu, Y.F., Botstein, D., Brown, P.O., Der, C.J., Tamanoi, F., Andres, D.A. and Perou, C.M. (2001) RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer.  J. Biol. Chem. 276, 42259-42267. doi: 10.1074/jbc.M105888200. 

105. Tamanoi, F., Gau, C.L., Edamatsu, H., Jiang, C. and Kato-Stankiewicz, J. (2001) Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell. Mol. Life Sci. 58, 1-14. doi: 10.1007/PL00000802. 

106. Yang, W., Tabancay, A.P.Jr., Urano, J. and Tamanoi, F. (2001) Failure to farnesylated Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant. Mol. Microbio. 41, 1339-1347. doi: 10.1046/j.1365-2958.2001.02599.x. 

107. Pervin, S., Singh, R., Gau, C-L., Edamatsu, H., Tamanoi, F. and Chaudhuri, G. (2001) Potentiation of nitric oxide induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: Implications in breast cancer. Cancer Res. 61, 4704-4706.

108. Guo, W., Tamanoi, F. and Novick, P. (2001) Spatial regulation of the exocyst complex by Rho1 GTPase. Nature Cell Biol. 3, 353-360. doi: 10.1038/35070029. 

109. Urano, J., Ellis, C., Clark, G.J. and Tamanoi, F. (2000) Characterization of Rheb function using yeast and mammalian systems. Methods in Enzymology 333, 217-231. doi: 10.1016/s0076-6879(01)33058-6. 

110. Chia, S., Urano, J., Tamanoi, F., Dunn, B. and Zink, J.I. (2000) Patterned arrays of living cells in Sol-Gel silica films. J. Am. Chem. Soc. 122, 6488-6489. doi: 10.3390/c4020029. 

111. Urano, J., Yang, W. and Tamanoi, F. (2000) Mutational analyses of protein farnesyltransferase.  In The Enzymes, vol 21, Protein Lipidation. (eds. Tamanoi and Sigman), Academic Press, San Diego, CA, pp 48-80.

112. Tamanoi, F., Del Villar, K., Robinson, N.G.G., Urano, J. and Yang, W. (2000) Genetic analysis of FTase and GGTase I and natural product farnesyltransferase inhibitors. In Farnesyltransferase and geranylgeranyltransferase I: Targets for cancer and cardiovascular therapy.  (eds, Sebti and Hamilton) Humana press, Totowa, NJ, pp 145-157.

113. Edamatsu, H., Gau, C-L., Nemoto, T., Guo, L. and Tamanoi, F. (2000) Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.  Oncogene 19, 3059-3068. doi: 10.1038/sj.onc.1203625. 

114. Urano, J., Tabancay, A.P., Yang, W. and Tamanoi, F. (2000) The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake.  J. Biol. Chem 275, 11198-11206. doi: 10.1074/jbc.275.15.11198. 

115. Yang, W., Urano, J. and Tamanoi, F. (2000) Protein farnesylation is critical for maintaining normal cell morphology and canavanine resistance in Schizosaccharomyces pombe. J. Biol. Chem. 275, 429-438. doi: 10.1074/jbc.275.1.429. 

116. Del Villar, K., Urano, J., Guo, L. and Tamanoi, F. (1999) A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors. J. Biol. Chem. 274, 27010-27017. doi: 10.1074/jbc.274.38.27010. 

117. Urano, J. and Tamanoi, F. (1999) Reconstitution of yeast farnesyltransferase from individually purified subunits.  In Protein Lipidation Protocols, ed. M. Gelb, Humana Press, NJ, 145-159. doi: 10.1385/1-59259-264-3:145. 

118. Robinson, N.G.G., Guo, L., Imai, J., Toh-e, A., Matsui, Y. and Tamanoi, F. (1999) Rho3 of Saccharomyces cerevisiae, which regulated the actin cytoskeleton and exocytosis, is a GTPase which interacts with Myo2 and Exo70.  Mol. Cell. Biol. 19, 3580-3587. doi: 10.1128/MCB.19.5.3580. 

119. Suzuki, N., Urano, J. and Tamanoi, F. (1998) Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc. Natl. Acad. Sci. USA 95, 15356-15361. doi: 10.1073/pnas.95.18.10499. 

120. Suzuki, N., Del Villar, K. and Tamanoi, F. (1998) Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells which are blocked by microtubule interfering agents. Proc. Natl. Acad. Sci. USA 95, 10499-10504. doi: 10.1073/pnas.95.18.10499.  

121. Arellano, M., Coll, P.M., Yang, W., Duran, A., Tamanoi, F. and Perez, P. (1998) Characterization of geranylgeranyl transferase type I from Schizosaccharomyces pombe. Molecular Microbiology, 29, 1357-1367. doi: 10.1046/j.1365-2958.1998.01009.x. 

122. Kim, M.R. and Tamanoi, F. (1998) Neurofibromatosis 1 GTPase activating protein-related domain and its functional significance.  In Neurofibromatosis type 1: from genotype to phenotype. (Upadhyaya, M. and Cooper, D.N. eds) BIOS Scientific, Oxford, UK. pp 89-112.

123. Scoles, D.R., Huynh, D.P., Morcos, P.A., Coulsell, E.R., Robinson, N.G.G., Tamanoi, F. and Pulst, S.M. (1998) Neurofibromatosis 2 tumor suppressor schwannomin interacts with bII-spectrin. Nature Genet. 18, 354-359. doi: 10.1038/ng0498-354. 

124. Yang, W., Del Villar, K., Urano, J., Mitsuzawa, H. and Tamanoi, F. (1997) Advances in the development of farnesyltransferase inhibitors: Substrate recognition by protein farnesyltransferase.  J. Cellular Biochem, S27, 12-19.

125. Upadhaya, M, Osborn, M., Maynard, J., Kim, M.R., Tamanoi, F. and Cooper, D. (1997) Mutational and functional analysis in the neurofibromatosis type 1 (NF1) gene. Human Genet. 99, 88-92. doi: 10.1007/s004390050317.

126. Del Villar, K., Mitsuzawa, H., Yang, W-L, Sattler, I. and Tamanoi, F. (1997) Amino acid substitutions which convert the protein substrate specificity of farnesyltransferase to that of geranylgeranyltransferase I. J. Biol. Chem. 272, 680-687. doi: 10.1074/jbc.272.1.680. 

127. Sattler, I. and Tamanoi, F. (1996) Prenylation of Ras and inhibitors of prenyltransferases. In Regulation of the RAS signalling network (ed. H. Maruta) Molecular Biology Intelligence Unit Series, R.G. Landes, Austin, TX.  pp 95-137.

128. Del Villar, K., Dorin, D., Sattler, I., Urano, J., Poullet, P., Robinson, N., Mitsuzawa, H. and Tamanoi, F. (1996)   C-terminal motifs found in Ras-superfamily G-proteins: CAAX and C-seven motifs. Biochem Soc. Trans. 24, 709-713. doi: 10.1042/bst0240709. 

129. Morcos, P., Thapar, N., Tusneem, N., Stacey, D. and Tamanoi, F. (1996) Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles. Mol. Cell. Biol. 16, 2496-2503. doi: 10.1128/MCB.16.5.2496. 

130. Tamanoi, F. (1996) RAM2. In Guidebook to the small GTPases (eds. Zerial, M. and Huber, L.) Oxford University Press, 50-52.

131. Tamanoi, F. (1996) DPR1/RAM1. In Guidebook to the small GTPases (eds. Zerial, M. and Huber, L.) Oxford University Press, 52-56.

132. Dorin, D., Cohen, L., DelVillar, K., Poullet, P., Mohr, R., Whiteway, M., Witte, O. and Tamanoi, F. (1995) Kir, a novel ras-family G-protein induces pseudohyphal growth in Saccharomyces cerevisiae. Oncogene 11, 2267-2271.

133. Baba, H., Fuss, B., Urano, J., Poullet, P., Watson, J.B., Tamanoi, F. and Macklin, W.B. (1995) GapIII, a new brain-enriched member of the GTPase-activating protein family. J. Neurosci. Res. 41, 846-858. doi: 10.1002/jnr.490410615. 

134. Gelb, M.H., Tamanoi, F., Yokoyama, K., Ghomashchi, F., Esson, K. and Gould, M.N. (1995) The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Letters 91, 169-175. doi: 10.1016/0304-3835(95)03747-k.

135. Poullet, P. and Tamanoi, F. (1995) Use of the yeast two-hybrid system to evaluate Ras interactions with neurofibromin-GAP. Methods in Enzymology 255, 488-497. doi: 10.1016/s0076-6879(95)55051-8.

136. Tamanoi, F. and Mitsuzawa, H. (1995) Use of yeast for the identification of farnesyltransferase inhibitors and for generation of mutant farnesyltransferases. Methods in Enzymology 255, 82-91. doi: 10.1016/s0076-6879(95)55011-9. 

137. Mitsuzawa, H. and Tamanoi, F. (1995) In vivo assays for farnesyltransferase inhibitors with Saccharomyces cerevisiae. Methods in Enzymology 250, 43-51. doi: 10.1016/0076-6879(95)50061-8. 

138. Mitsuzawa, H., Esson, K. and Tamanoi, F. (1995) Mutant farnesyltransferase ß subunit of Saccharomyces cerevisiae that can substitute for geranylgeranyltransferase type I ß subunit. Proc. Natl. Acad. Sci. USA 92, 1704-1708. doi: 10.1073/pnas.92.5.1704. 

139. Cohen, L., Mohr, R., Chen, Y-Y, Huang, M., Kato, R., Dorin, D., Tamanoi, F., Goga, A., Afar, D., Rosenberg, N. and Witte, O. (1994) Transcriptional activation of a novel ras-like gene (kir) by oncogenic tyrosine kinases. Proc. Natl. Acad. Sci. USA 91, 12448-12452. doi: 10.1073/pnas.91.26.12448. 

140. Wood, D.R., Poullet, P., Wilson, B.A., Khalil, M., Tanaka, K., Cannon, J.F. and Tamanoi, F. (1994) Biochemical characterization of yeast RAS2 mutants reveals a new region of ras protein involved in the interaction with GTPase activating proteins. J. Biol. Chem. 269, 5322-5327.

141. Poullet, P., Lin, B., Esson, K. and Tamanoi, F. (1994) Functional significance of lysine-1423 of neurofibromin and characterization of a second site suppressor which rescues mutation at this residue and suppresses RAS2val19 activated phenotypes. Mol. Cell. Biol. 14, 815-821. doi: 10.1128/mcb.14.1.815-821.1994. 

142. Diaz, M., Sanchez, Y., Bennett, T., Sun, C.R., Godoy, C., Tamanoi, F., Duran, A. and Perez, P. (1993) The Schizosaccharomyces pombe cwg2+ gene codes for the ß subunit of a geranylgeranyltransferase type I required for ß-glucan synthesis. The EMBO Journal. 12, 5245-5254.

143. Wilson, B., Khalil, M., Tamanoi, F. and Cannon, J.F. (1993) New activated RAS2 mutations identified in Saccharomyces cerevisiae. Oncogene, 8, 3441-3445.

144. Tamanoi, F. (1993) Inhibitors of ras farnesyltransferases. TIBS, 18, 349-353. doi: 10.1016/0968-0004(93)90072-u. 

145. Hara, M., Akasaka, K., Akinaga, S., Okabe, M., Nakano, H., Gomez, R., Wood, D., Uh, M. and Tamanoi, F. (1993) Identification of ras farnesyltransferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. USA 90, 2281-2285. doi: 10.1073/pnas.90.6.2281. 

146. Gomez, R., Goodman, L.E., Tripathy, S.K., O'Rourke, E., Manne, V. and Tamanoi, F. (1993) Purified yeast protein farnesyltransferase is structurally and functionally similar to its mammalian counterpart. Biochem. J.,289, 25-31. doi: 10.1042/bj2890025. 

147. Tanaka, K., Wood, D.R., Lin, B.K., Khalil, M., Tamanoi, F. and Cannon, J.F. (1992) A dominant activating mutation in the effector region of RAS abolishes IRA2 sensitivity. Mol. Cell. Biol. 12, 631-637. doi: 10.1128/mcb.12.2.631-637. 

148. McNeel, D.G. and Tamanoi, F. (1991) Terminal region recognition factor 1, a DNA-binding protein recognizing the inverted terminal repeats of the pGKl linear DNA plasmids. Proc. Natl. Acad. Sci. USA 88, 11398-11402. doi: 10.1073/pnas.88.24.11398. 

149. Golubic, M., Tanaka, K., Dobrowski, S., Wood, D., Tsai, M.H., Marshall, M., Tamanoi, F. and Stacey, D.W. (1991) The GTPase stimulatory activities of the neurofibromatosis type 1 and the yeast IRA2 proteins are inhibited by arachidonic acid. The EMBO J. 10, 2897-2903.

150. Fujiyama, A., Tsunasawa, S., Tamanoi, F. and Sakiyama, F. (1991) S-Farnesylation and methyl esterification of C-terminal domain of yeast RAS2 protein prior to fatty acid acylation. J. Biol. Chem 266, 17926-17931.

151. Ohya, Y., Goebel, M., Goodman, L.E., Petersen-Bjorn, S., Friesen, J.D., Tamanoi, F. and Anraku, Y. (1991) Yeast CAL1 is a structural and functional homologue to the DPR1 (RAM) gene involved in ras processing. J. Biol. Chem. 266, 12356-12360.

152. Finegold, A.A., Johnson, D.I., Farnsworth, C.C., Gelb, M.H., Judd, S.R., Glomset, J.A. and Tamanoi, F. (1991) Protein geranylgeranyl transferase of Saccharomyces cerevisiae is specific for Cys-Xaa-Xaa-Leu motif proteins and requires the CDC43 gene product, but not the DPR1 gene product. Proc. Natl. Acad. Sci. USA 88, 4448-4452. doi: 10.1073/pnas.88.10.4448. 

153. Judd, S.R. and Tamanoi, F. (1991) A genetic approach to the study of farnesylation. "Methods" A companion to Methods in Enzymology 1, 246-252.

154. Tanaka, K., Lin, B.K., Wood, D.R. and Tamanoi, F. (1991) IRA2, an upstream negative regulator of RAS in yeast, is a RAS GTPase activating protein (GAP). Proc. Natl. Acad. Sci. USA 88, 468-472. doi: 10.1073/pnas.88.2.468. 

155. Goodman, L.E., Judd, S.E., Farnsworth, C.C., Powers, S., Gelb, M.H., Glomset, J.A. and Tamanoi, F. (1990) Mutants of Saccharomyces cerevisiae defective in the farnesylation of ras proteins. Proc. Natl. Acad. Sci. USA 87, 9665-9669. doi: 10.1073/pnas.87.24.9665. 

156. Xu, G., Lin, B., Tanaka, K., Dunn, D., Wood, D., Gesteland, R., Weiss, R. and Tamanoi, F. (1990) The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements iramutants of S. cerevisiae. Cell 63, 835-841. doi: 10.1016/0092-8674(90)90149-9. 

157. Tanaka, K., Nakafuku, M., Tamanoi, F., Kaziro, Y., Matsumoto, K., and Toh-e, A. (1990) IRA2, a second gene of Saccharomyces cerevisiae that encodes a protein with a domain homologous to mammalian ras GTPase activating protein. Mol. Cell. Biol. 10, 4303-4313. doi: 10.1128/mcb.10.8.4303-4313.1990. 

158. Finegold, A.A., Schafer, W.R., Rine, J., Whiteway, M., and Tamanoi, F. (1990) Common modifications of trimeric G proteins and ras protein: Involvement of polyisoprenylation. Science 249, 165-171. doi: 10.1126/science.1695391.  

159. Fujiyama, A. and Tamanoi, F. (1990) RAS2 protein of S. cerevisiae undergoes removal of methionine at N-terminus and removal of three amino acids at C-terminus. J. Biol. Chem. 265, 3362-3368.

160. Tamanoi, F., Cobitz, A.R., Fujiyama, A., Goodman, L.E. and Perou, C.M. (1989) Post-translational modification of ras proteins: Palmitoylation and phosphorylation of yeast RAS proteins. In: RAS Oncogenes (ed. D. Spandidos) Plenum Press, New York and London, 225-233. doi: 10.1007/978-1-4757-1235-3_29. 

161. Cobitz, A.R., Yim E.H., Brown, W.R., Perou, C.M. and Tamanoi, F. (1989) Phosphorylation of RAS1 and RAS2 proteins in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 86, 858-862. doi: 10.1073/pnas.86.3.858. 

162. Goodman, L.E., Perou, C.M., Fujiyama, A. and Tamanoi, F. (1988) Structure and expression of yeast DPR1, a gene essential for the processing and intracellular localization of ras proteins. Yeast 4, 271-281. doi: 10.1002/yea.320040405. 

163. Tamanoi, F. (1988). Yeast RAS genes. Biochem. Biophys. Acta 948, 1-15. doi: 10.1016/0304-419x(88)90002-9. 

164. Tamanoi, F., Hseuh, E.C., Goodman, L.E., Cobitz, A.R., Detrick, R.J., Brown, W.R., and Fujiyama, A. (1988) Post-translational modification of ras proteins: Detection of a modification prior to fatty acid acylation and cloning of a gene responsible for the modification. J. Cell. Biochem. 36, 261-273. doi: 10.1002/jcb.240360307. 

165. Fujiyama, A., Matsumoto, K., and Tamanoi, F. (1987) A novel yeast mutant deficient in the processing of ras proteins: Assessment of the effect of the mutation on processing steps. EMBO J. 6, 223-228.

166. Fujiyama, A., Samiy, N., Rao, M. and Tamanoi, F. (1986) Biochemistry of yeast RAS1 and RAS2 proteins. In: Yeast Cell Biology (ed. Hicks, J.) Alan R. Liss, Inc., New York, pp. 125-149.

167. Fujiyama, A. and Tamanoi, F. (1986) Processing and fatty acylation of RAS1 and RAS2 proteins in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 83, 1266-1270. doi: 10.1073/pnas.83.5.1266. 

168. Tamanoi, F. (1986) On the mechanism of adenovirus DNA replication. In: Develop-ments in Molecular Virology Vol. 8, "Adenovirus DNA: The Viral Genome and Its Expression" (W. Doerfler, ed.), Martinus Nijhoff Publishing, Boston, pp. 97-128. 

169. Broek, D., Samiy, N., Fasano, O., Fujiyama, A., Tamanoi, F., Northup, J., and Wigler, M. (1985) Differential activation of yeast adenylate cyclase by wild-type and mutant RAS proteins. Cell 41, 763-769. doi: 10.1016/s0092-8674(85)80057-x. 

170. Tamanoi, F., Rao, M., Samiy, N., and Walsh, M. (1985) Enzymatic properties of yeast RAS2 protein. In: Cancer Cells 3, 251-256 (Cold Spring Harbor Laboratory).

171. Tamanoi, F., Walsh, M., Kataoka, T., and Wigler, M. (1984) A product of yeast RAS2 gene is a guanine nucleotide binding protein. Proc. Natl. Acad. Sci. USA 81, 6924-6928. doi: 10.1073/pnas.81.22.6924. 

172. Hughes, S., Mellstrom, K., Kosik, E., Tamanoi, F., and Brugge, J. (1984) Mutation of a termination codon affects src initiation. Mol. Cell. Biol. 4, 1738-1746. doi: 10.1128/mcb.4.9.1738-1746.1984. 

173. Fasano, O., Aldrich, T., Tamanoi, F., Taparowsky, E., Furth, M. and Wigler, M. (1984) Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proc. Natl. Acad. Sci. USA 81, 4008-4012. doi: 10.1073/pnas.81.13.4008. 

174. Guggenheimer, R.A., Stillman, B.W., Nagata, K., Tamanoi, F. and Hurwitz, J. (1984) DNA sequences required for the in vitro replication of adenovirus DNA. Proc. Natl. Acad. Sci. USA 81, 3069-3073. doi: 10.1073/pnas.81.10.3069. 

175. Tamanoi, F. and Stillman, B.W. (1983) The origin of adenovirus DNA replication. In: Current Topics in Microbiology and Immunology. 109, 75-87.

176. Tamanoi, F., and Stillman, B.W. (1983) Initiation of adenovirus DNA replication in vitro requires a specific DNA sequence. Proc. Natl. Acad. Sci. USA 80, 6446-6450. doi: 10.1073/pnas.80.21.6446. 

177. Stillman, B.W. and Tamanoi, F. (1983) Adenoviral DNA replication: DNA sequences and enzymes required for initiation in vitro. Cold Spring Harbor Symp. Quant. Biol. 47, 741-750. doi: 10.1101/sqb.1983.047.01.085. 

178. Stillman, B.W., Tamanoi, F., and Mathews, M.B. (1982) Purification of an adenovirus coded DNA polymerase that is required for initiation of DNA replication. Cell 31, 613-623. doi: 10.1016/0092-8674(82)90317-8. 

179. Tamanoi, F., and Stillman, B.W. (1982) Function of adenovirus terminal protein in the initiation of DNA replication. Proc. Natl. Acad. Sci. USA 79, 2221-2225. doi: 10.1073/pnas.79.7.2221. 

180. Deuring, R., Winterhoff, U., Tamanoi, F., Stabel, S., and Doerfler, W. (1981) Site of linkage between adenovirus type 12 and cell DNAs In hamster tumor line CLAC3. Nature 293, 5827, 81-84. doi: 10.1038/293081a0. 

181. Romano, L.J., Tamanoi, F. and Richardson, C.C. (1981) Initiation of DNA repication at the primary origin of bacteriophage T7 by purified proteins: requirements for T7 RNA polymerase. Proc. Natl. Acad. Sci. USA 78, 4107-4111. doi: 10.1073/pnas.78.7.4107.  

182. Tamanoi, F., Engler, M.J., Lechner, R., Orr-Weaver, T., Romano, L.J., Saito, H., Tabor, S. and Richardson, C.C. (1980) In: Mechanistic Studies of DNA Replication and Genetic Recombination, (B. Alberts, ed.) Academic Press, New York, pp. 411-428.

183. Saito, H., Tabor, S., Tamanoi, F. and Richardson, C.C. (1980) Nucleotide sequence of the primary origin of bacteriophage T7 DNA replication: relationship to adjacent genes and regulatory elements. Proc. Natl. Acad. Sci. USA 77, 3917-3921. doi: 10.1073/pnas.77.7.3917.  

184. Tamanoi, F., Saito, H. and Richardson, C.C. (1980) Physical mapping of primary and secondary origins of bacteriophage T7 DNA replication. Proc. Natl. Acad. Sci. USA 77, 2656-2660. doi: 10.1073/pnas.77.5.2656. 

185. Campbell, J.L., Tamanoi, F., Richardson, C.C. and Studier, F.W. (1979) Cloning of the T7 genome in E. coli: Use of recombination between cloned sequences and bacteriophage T7 to identify genes involved in recombination and a clone containing the origin of T7 DNA replication. Cold Spring Harbor Symp. Quant. Biol. 443, 441-448. doi: 10.1101/sqb.1979.043.01.050. 

186. Richardson, C.C., Romano, L.J., Kolodner, R., LeClerc, J.E., Tamanoi, F., Engler, M.J., Dean, F.B. and Richardson, D.S. (1979) Replication of bacteriophage T7 DNA by purified proteins. Cold Spring Harbor Symp. Quant. Biol. 43, 427-440. doi: 10.1101/sqb.1979.043.01.049.  

187. Tamanoi, F., Machida, Y. and Okazaki, T. (1979) Uracil incorporation into nascent DNA by B. subtilis and E. coli. Cold Spring Harbor Symp. Quant. Biol. 43, 239-242. doi: 10.1101/sqb.1979.043.01.029. 

188. Okazaki, T., Kurosawa, Y., Ogawa, T., Seki, T., Shinozaki, K., Hirose, S., Fujiyama, A., Kohara, Y., Machida, Y., Tamanoi, F. and Hozumi, T. (1979). Structure and metabolism of the RNA primer in the discontinuous replication of prokaryotic DNA. Cold Spring Harbor Symp. Quant. Biol. 43, 203-219. doi: 10.1101/sqb.1979.043.01.026. 

189. Tamanoi, F. and Okazaki, T. (1978) Uracil incorporation into nascent DNA fragments of thymine requiring mutant of B. subtilis 168. Proc. Natl. Acad. Sci. USA 75, 2195-2199. doi: 10.1073/pnas.75.5.2195. 

190. Tamanoi, F., Okazaki, T. and Okazaki, R. (1977) Persistance of RNA attached to nascent short DNA pieces in Bacillus subtilis cells defective in DNA polymerase I. Biochem. Biophys. Res. Commun. 77, 290-297. doi: 10.1016/s0006-291x(77)80195-2. 

191. Tamanoi, F., Uchida, T., Egami, F. and Oshima, T. (1976) Synthesis of various phosphodiesters and phosphomonoesters with ribonuclease N. J. Biochem. 80, 27-32. doi: 10.1093/oxfordjournals.jbchem.a131253. 

192. Okazaki, R., Okazaki, T., Hirose, S., Sugino, A., Ogawa, T., Kurosawa, Y., Shinozaki, K., Tamanoi, F., Seki, T., Machida, Y., Fujiyama, A. and Kohara, Y. (1975) Discontinuous replication in prokaryotic systems. In: DNA Synthesis and Its Regulation, Vol. III. (M. Goulian & P. Hanawalt, eds.; F. Fox series ed.) ICN-UCLA Symposium on Molecular and Cellular Biology, W.A. Benjamin, California, p.832.

193. Hirose, S., Okazaki, R. and Tamanoi, F. (1973) Mechanism of DNA chain growth. XI. Structure of RNA-linked DNA fragments of E. coli. J. Mol. Biol. 77, 501-517. doi: 10.1016/0022-2836(73)90219-2.